# Favorable Effects of Atrial Fixation Transcatheter Mitral Valve Replacement on Left Atrium Volume and Strain

**Authors:** Nadira Hamid, Paul Grayburn, Vlasis Ninios, Krzysztof Wrobel, Naeem Tahirkheli, Ron Waksman, Michael Rinaldi, Marek Grygier, Philippe Genereux, Paul Sorajja

PMC · DOI: 10.1016/j.jacadv.2025.102236 · 2025-10-16

## TL;DR

This study shows that the AltaValve System reduces left atrium volume and strain in patients with severe mitral regurgitation.

## Contribution

The study demonstrates favorable effects of a specific TMVR system on left atrium remodeling and function.

## Key findings

- Left atrium volume significantly decreased at 6-month follow-up.
- Reservoir and conduit phase strain of the left atrium improved significantly.
- Exercise capacity and functional status improved in most patients.

## Abstract

The AltaValve System transcatheter mitral valve replacement (TMVR) has a spherical nitinol frame designed to fit the left atrium (LA) in a compliant fashion.

The objective of the study was to evaluate the anatomical and functional changes of the LA with the AltaValve System.

A total of 16 patients with severe, symptomatic mitral regurgitation who underwent AltaValve System transcatheter mitral valve replacement implantation via either a transseptal (n = 8) or transapical (n = 8) approach were examined. Transthoracic echocardiography was performed at baseline and 6-month follow-up. LA volumes and strain were evaluated using dedicated software (TomTec) with paired statistical testing.

All patients (median age, 77 years; 75% women [12/16]) had successful implantation. Most had atrial fibrillation (87%) and normal/reduced left ventricular ejection fraction. There was significant reduction in LA volume at 6 months (117.4 ± 39 mL vs 93.0 ± 37.0 mL; P = 0.002). For LA strain, there was significant reduction in both reservoir (10.8% ± 5.8% vs 1.6% ± 2.1%; P < 0.001) and conduit phase (−9.7% ± 3.2% vs −4.2% ± 4.4%; P = 0.013) of LA cycle. There were no significant change in the contraction phase (−1.1% vs −2.7%; P = 0.079). There was significant improvement in exercise capacity among 13 patients (average 6-minute walk test distance from 253 m at baseline to 296 m) and in functional status 55.1 ± 20.5 at baseline to 67.0 ± 22.5 (P = 0.04) at 6-month follow-up. For the responders, there were statistically significant differences at 6-month follow-up for majority of the LA parameters including strain.

There was a presence of LA remodeling following AltaValve System implantation and this was accompanied by a reduction in LA strain for both the reservoir and conduit phases, without changes in contractility.

## Linked entities

- **Diseases:** atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Diseases:** mitral regurgitation (MESH:D008944), atrial fibrillation (MESH:D001281)
- **Chemicals:** AltaValve (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12553041/full.md

---
Source: https://tomesphere.com/paper/PMC12553041